Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Current Neurology and Neuroscience Reports
Published in: Current Neurology and Neuroscience Reports 2/2014

01-02-2014 | Headache (R Halker, Section Editor)

New Daily Persistent Headache and Potential New Therapeutic Agents

Authors: Shivang G. Joshi, Paul G. Mathew, Herbert G. Markley

Published in: Current Neurology and Neuroscience Reports | Issue 2/2014

Login to get access

Abstract

New daily persistent headache is a form of a chronic daily headache with a unique temporal profile. Patients can recall the exact day when their headache started. It can be one of the most refractory types of headache to treat. Recent publications have highlighted different subtypes and heterogeneity in presentation. Referring to it as a syndrome versus a distinct disorder has also been suggested. Several different classes of medications have been used for the treatment, with mixed results. The underlying pathophysiology of new daily persistent headache is unclear, but tumor necrosis factor may play a role. The clinical features, differential diagnosis and potential new therapeutic agents will be discussed.
Literature
1.•
Vanast WJ. New daily persistent headaches definition of a benign syndrome. Headache. 1986;26:318. The first description of NDPH.
2.
3.
Castillo J, Muñoz P, Guitera V, Pascual J. Epidemiology of chronic daily headache in the general population. Headache. 1999;39:190–6.PubMedCrossRef
4.
Li D, Rozen TD. The clinical characteristics of new daily persistent headache. Cephalalgia. 2002;22:66–9.PubMedCrossRef
5.
Silberstein SD, Lipton RB. Chronic daily headache, including transformed migraine, chronic tension-type headache and medication overuse. In: Silberstein SD, Lipton RB, Dalessio DJ, editors. Wolff’s headache and other head pain. Oxford: Oxford University Press; 2001. p. 247–82.
6.
The International Classification of Headache Disorders, 2nd edition. Cephalalgia. 2004; 24(Suppl. 1): 9–160.
7.
Kung E, Tepper SJ, Rapoport AM, Sheftell FD, Bigal ME. New daily persistent headache in the paediatric population. Cephalalgia. 2009;29:17–22.PubMedCrossRef
8.••
Robbins MS, Grosberg BM, Napchan U, et al. Clinical and prognostic subforms of new daily-persistent headache. Neurology. 2010;74:1358–64. Important article that identifies clinical and prognostic subtypes of NDPH.PubMedCrossRef
9.
Robbins MS, Evans RW. The heterogeneity of new daily persistent headache. Headache. 2012;52:1579–89.PubMedCrossRef
10.••
Goadsby PJ. New daily persistent headache: a syndrome, not a discrete disorder. Headache. 2011;51:650–3. This article brings to light the complexity of NDPH, and asserts that it is a syndrome rather than a specific disorder.PubMedCrossRef
11.
Rozen TD. Intranasal contact point headache: missing the “point” on brain MRI. Neurology. 2009;72:1107.PubMedCrossRef
12.
Harrison L, Jones NS. Intranasal contact points as a cause of facial pain or headache: a systematic review. Clin Otolaryngol. 2013;38:8–22.PubMedCrossRef
13.
14.
de Sousa Aguiar D, Geraldes R, Gil-Gouveia R, de Sá JC. New daily persistent headache and radiologically isolated syndrome. J Neurol. 2013;260(8):2179–81.CrossRef
15.
16.
Diaz-Mitoma F, Vanast WJ, Tyrrell DLJ. Increased frequency of Epstein-Barr virus excretion in patients with new daily persistent headaches. Lancet. 1987;1:411–5.PubMedCrossRef
17.
Santoni JR, Santoni-Williams CJ. Headache and painful lymphadenopathy in extracranial or systemic infection: etiology of new daily persistent headaches. Intern Med. 1993;32:530–2.PubMedCrossRef
18.
19.
Rozen TD, Roth JM, Denenberg N. Cervical spine joint hypermobility: a possible predisposing factor for new daily persistent headache. Cephalalgia. 2006;26:1182–5.PubMedCrossRef
20.
Dohle C, Baehring JM. Multiple strokes and bilateral carotid dissections: a fulminant case of newly diagnosed Ehlers-Danlos syndrome type IV. J Neurol Sci. 2012;318:168–70.PubMedCrossRef
21.
22.
Rozen T, Swidan SZ. Elevation of CSF tumor necrosis factor alpha levels in new daily persistent headache and treatment refractory chronic migraine. Headache. 2007;47:1050–5.PubMedCrossRef
23.
24.
Prakash S, Shah ND. Post-Infectious new daily persistent headache may respond to intravenous methylprednisolone. J Headache Pain. 2010;1:59–66.CrossRef
25.
26.
Tsakadze N, Wilson MC. Abstract B26, The 4th World Congress on Controversies in Neurology (CONy) Oct. 28, 2010 - Oct 31, 2010. Barcelona, Spain.
27.
Rozen TD. Doxycycline for treatment resistant new daily persistent headache. Neurology. 2008;70 Suppl 1:A348.
28.
Marmura MJ, Passero FC, Young WB. Mexiletine for refractory chronic daily headache: a report of nine cases. Headache. 2008;48:1506–10.PubMedCrossRef
29.
Rozen TD. Successful treatment of new daily persistent headache with gabapentin and topiramate. Headache. 2002;42:433.
30.
San-Emeterio EP, Hurlé MA. Modulation of brain apoptosis-related proteins by the opioid antagonist naltrexone in mice. Neurosci Lett. 2006;403:276–9.PubMedCrossRef
31.
Greeneltch KM, Haudenschild CC, Keegan AD, Shi Y. The opioid antagonist naltrexone blocks acute endotoxic shock by inhibiting tumor necrosis factor-alpha production. Brain Behav Immunol. 2004;18:476–84.CrossRef
32.
33.
Younger J. American Academy of Pain Medicine (AAPM) 28th Annual Meeting: abstract 251. February 24, 2012.
34.
Rapoport AM, Bigal ME, Volcy M, Sheftell FD, Feleppa M, Tepper SJ. Naratriptan in the preventive treatment of refractory chronic migraine: a review of 27 cases. Headache. 2003;43:482–9.PubMedCrossRef
35.
Sheftell FD, Rapoport AM, Tepper SJ, Bigal ME. Naratriptan in the preventive treatment of refractory transformed migraine: a prospective pilot study. Headache. 2005;45:1400–6.PubMedCrossRef
36.
Gallagher RM, Mueller L. Managing intractable migraine with naratriptan. Headache. 2003;43:991–3.PubMedCrossRef
37.
Ruff RL, Ruff SS, Wang XF. Improving sleep: initial headache treatment in OIF/OEF veterans with blast-induced mild traumatic brain injury. J Rehabil Res Dev. 2009;46:1071–84.PubMedCrossRef
Metadata
Title
New Daily Persistent Headache and Potential New Therapeutic Agents
Authors
Shivang G. Joshi
Paul G. Mathew
Herbert G. Markley
Publication date
01-02-2014
Publisher
Springer US
Published in
Current Neurology and Neuroscience Reports / Issue 2/2014
Print ISSN: 1528-4042
Electronic ISSN: 1534-6293
DOI
https://doi.org/10.1007/s11910-013-0425-5

Other articles of this Issue 2/2014

Current Neurology and Neuroscience Reports 2/2014 Go to the issue

Nerve and Muscle (L Weimer, Section Editor)

Recent Advances in Myotonic Dystrophy Type 2

Headache (R Halker, Section Editor)

Migraine and Patent Foramen Ovale

Sleep (M Thorpy, M Billiard, Section Editors)

Nocturnal Frontal Lobe Epilepsy

Headache (R Halker, Section Editor)

Insights and Advances in Post-traumatic Headache: Research Considerations

Headache (R Halker, Section Editor)

Migralepsy: A Borderland of Wavy Lines

Sleep (M Thorpy, M Billiard, Section Editors)

Differential Effects of Non-REM and REM Sleep on Memory Consolidation?